are compounded glp 1 still available GLP-1 Managing Compounded GLP-1 Medications: A

At the State Level: The real momentum for reform has been at the state level, with 2025 being dubbed the year of PBM reform

Notably, cold acclimation has been found to enhance peripheral insulin sensitivity in individuals with type 2 diabetes 1

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape

For many patients, it is the primary mechanism driving results

He utilizes a team-based approach to mental healthcare, working alongside patients and their therapists